Open-label Phase 3 Study of MK-7684A (Coformulation of Vibostolimab With Pembrolizumab) in Combination With Concurrent Chemoradiotherapy Followed by MK-7684A Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Unresectable, Locally Advanced, Stage III NSCLC
This study is to evaluate the safety and efficacy of pembrolizumab/vibostolimab (MK-7684A) in
combination with concurrent chemoradiotherapy (cCRT) followed by pembrolizumab/vibostolimab
versus cCRT followed by durvalumab in participants with unresectable, locally advanced, stage
III Non-small Cell Lung Cancer (NSCLC). The primary hypotheses are that
pembrolizumab/vibostolimab with cCRT followed by pembrolizumab/vibostolimab is superior to
cCRT followed by durvalumab with respect to the following:
progression free survival (PFS) per Response Evaluation Criteria In Solid Tumors
(RECIST) version 1.1 by blinded independent central review (BICR) in participants with
programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥1% and PD-L1 all
overall survival (OS) in participants with PD-L1 TPS ≥1% and PD-L1 all comer
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.